MIAMI, FL / ACCESSWIRE / July 26, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics in the extracellular vesicle space, announced today that the board of directors has appointed Matt Sinnreich as Chief Operating Officer and acting CEO. Sinnreich will replace Mr. Albert Mitrani, […]
MIAMI, FL / ACCESSWIRE / July 20, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of related services, announced today that it has secured $4.0 million in funding to finance clinical trials of its products […]
“Organicell Regenerative Medicine is amongst the first groups of innovators to spearhead the use of naturally occurring extracellular vesicles as a next-generation therapeutic tool for inflammatory and chronic disease.” Learn more about Organicell’s “Advances of Exosome-Based Therapeutics in the Clinic” in our most recent published article on Bioinformant. Read the full article
Miami, FL Miami (February 8, 2022)—Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has secured its first site to carry out the Organicell Phase I/II Multicenter, Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Zofin™ Infused Intravenous (IV) in Patients Experiencing […]
Join Organicell along with leading Expanded Access Program thinkers sharing their expertise and knowledge towards bringing treatments to patients in need. Secure your spot by registering today: https://operationalize-eap.com/take-part/register/?utm_source=digital&utm_medium=social-post&utm_campaign=other-general-promotion&utm_content=linkedin/organicell-speaker/ev-23689
MIAMI, FL / ACCESSWIRE / December 29, 2021 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, is pleased to provide its stockholders and the investment community with the following updates regarding its approved Investigational New Drug Applications (“IND”) and other clinical trial related activities surrounding Zofin™, its […]
Join Organicell along with leading developers, investors and solution providers looking to bring cell and gene therapies to patients. Secure your spot by registering today
“As progress is made in addressing the COVID-19 pandemic with vaccines and treatment pathways, reports about the long-term effects of the infection are building.” Pharmaceutical Executive in collaboration with Parexel organized a roundtable of experts from various stake-holder groups, including Organicell’s Chief Science Officer Dr. Mari Mitrani, to discuss the current research into long-haul COVID. Read […]
Organicell’s latest research publication is now available to read in Biomaterials and Biosystems Journal, “Proof-of-Concept Trial of an Amniotic Fluid-Derived Extracellular Vesicle Biologic for Treating High Risk Patients with Mild-to-Moderate Acute COVID-19 Infection”.
We have dedicated this to our Primary Investigator who didn’t have the chance to see it published. Thank you Dr. Friedewald, your career has greatly impacted us and has left us inspired to continue your legacy.
Read the full publication here.
Miami, FL (November 9, 2021) — Organicell Regenerative Medicine, Inc. (OTCQB: OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that its application to uplist its common stock to the OTCQB Venture Market (the “OTCQB”) has been approved by OTC Markets Group, Inc. Organicell’s common stock will commence trading on […]
LET’S STAY CONNECTED
Copyright © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Privacy Policy.